01 / 13

ABPN Fellowship-Level Training

Women & Perinatal Addiction Psychiatry

Evidence-Based Management for the 2026 Addiction Psychiatrist

80%

Women with SUD + Trauma History

6-12mo

Peak Overdose Mortality Postpartum

ESC

New NOWS Standard (not Finnegan)

Disclosure: This presentation addresses high-stakes perinatal care. Content aligned with ASAM, ACOG, and ABPN 2026 standards.

02 / 13

Session Framework

Learning Objectives

Scientific Foundations

Understand the "telescoping" effect
Sex-based differences in addiction neurobiology
Trauma-SUD nexus and MST in VA populations

MOUD in Pregnancy

Methadone vs. Buprenorphine selection
Third trimester dosing strategies
Intrapartum pain management

Neonatal Care

ESC model implementation
Breastfeeding on MOUD
NOWS severity correlation myths

Systems & Legal

CAPTA vs. CPS distinction
42 CFR Part 2 updates
Fourth trimester overdose prevention

03 / 13

Epidemiology & Physiology

The "Telescoping" Effect

Women progress from initiation to dependence faster than men
Estrogen mechanism: Modulates dopamine release in nucleus accumbens, heightening reward sensitivity
Clinical implication: 2-year history in woman ≈ 10-year history in man for severity
80-90% of women with SUD have trauma history (IPV, sexual assault, MST)
Overdose is leading cause of pregnancy-associated death (CDC MMWR 2024/2025)

      Board Trigger: Telescoping = rapid progression in females. Trauma: Must screen for IPV/MST—your med management will fail without addressing this.
    

04 / 13

Assessment

Screening & Consent

✓ Universal Verbal Screening

4P's Plus (Parents, Partner, Past, Pregnancy)
NIDA Quick Screen
CRAFFT (if <26 years)
ACOG mandate: NOT risk-based

! Urine Toxicology

Requires informed consent
Screening ≠ Testing
Ferguson v. City of Charleston (2001)
Non-consensual testing for prosecution = unconstitutional

      Clinical Pearl: "I test all my pregnant patients to ensure safety. Is that okay?" If refused, treat based on history—forced testing drives women from care.
    

05 / 13

Opioid Use Disorder

The Standard of Care

❌ DETOX IS CONTRAINDICATED ❌
Relapse rate: 59-90%
Intrauterine stress from withdrawal cycles
Loss of tolerance → overdose death
Patient/family will push for "clean baby" — educate firmly

✓ MOUD IS THE STANDARD ✓

Methadone or Buprenorphine stabilizes intrauterine environment. Naloxone IS safe in overdose—maternal hypoxia is fatal. "Save the mother to save the baby."

06 / 13

Pharmacotherapy

Methadone vs. Buprenorphine

Feature	Methadone	Buprenorphine
Setting	OTP (clinic)	Office-based or OTP
Retention	Higher for severe/chaotic	Good for stable patients
NOWS	Longer/potentially more severe	Milder (MOTHER study)
Dosing	Full agonist, no ceiling	Partial agonist, ceiling effect
Formulation	Liquid/diskettes	Mono or Combo (Suboxone OK in 2026)

      MOTHER Study: Buprenorphine = less severe NOWS. Update 2024-2025: Combo products (Suboxone) acceptable if diversion concern—naloxone has negligible fetal bioavailability.
    

07 / 13

Pharmacokinetics

The "Third Trimester Trough"

CYP3A4 induction: Progesterone revs up metabolism
Volume expansion: Plasma volume ↑ 50%
Patient stable on 80mg will be in withdrawal by 4 PM
Solution: SPLIT DOSING (BID/TID) or dose increase
Postpartum: Metabolism normalizes → risk of sedation

      Board Trap: "Patient 36 weeks, stable on methadone, now complaining of afternoon withdrawal." Answer: Split the dose (BID)—do not just increase morning dose. Metabolism is the issue, not total dose.
    

08 / 13

Neonatal Outcomes

NOWS: Eat, Sleep, Console

        ❌ OLD: Finnegan
        Counting sneezes, yawning
Checking reflexes
Waking baby to score
Over-treatment with morphine
NICU separation

      

        ✓ NEW: ESC (2024-2026)
        Can baby eat 1oz?
Can baby sleep 1 hour?
Can baby be consoled in 10 min?
If YES → don't medicate
Rooming-in with mom

      

      Breastfeeding on MOUD: Recommended—reduces NOWS severity by ~50%. Safe for methadone and buprenorphine. Contraindicated: Active stimulant use, HIV (if not controlled).
    

09 / 13

Other Substances

Alcohol & Sedatives

Alcohol: #1 Preventable Cause of Developmental Disability

No safe amount, no safe time. FASD: Smooth philtrum, thin upper lip, neurodevelopmental deficits.

Alcohol withdrawal: Medical emergency—must treat with benzos/phenobarbital
AUD pharmacotherapy: Naltrexone, Acamprosate; avoid Disulfiram (teratogenic)
Topiramate Warning: Induces CYP3A4 → OCP failure → cleft palate (teratogen)
Board Trap: "Female on OCPs requests Topiramate for migraines + drinking." Must use IUD.

10 / 13

Stimulant Use Disorder

Stimulants & Cannabis

Contingency Management = Gold Standard

SAMHSA Advisory PEP24-06-001: Only intervention with Grade A evidence for stimulant use disorder. Incentivizes negative urine screens.

Risks in pregnancy: Placental abruption, preterm labor, IUGR
Breastfeeding: Contraindicated with active stimulant use (direct toxicity)
Cannabis: ACOG advises cessation; THC concentrates in breast milk
Abruption presentation: Abdominal pain + vaginal bleeding + stimulant use = emergency

11 / 13

Postpartum Risk

The Fourth Trimester Danger Zone

Peak Mortality: 7–12 Months Postpartum

CDC MMWR 2024/2025: Maternal overdose mortality peaks late in the postpartum year—not at delivery.

Loss of tolerance: Abstinence in pregnancy → return to use at pre-pregnancy dose = fatal
Insurance churn: Verify 12-month Medicaid extension (now permanent option)
Sleep deprivation: Newborn care demands
PPE/PPD: Postpartum psychiatric complications
DON'T taper MOUD immediately postpartum

12 / 13

Legal Frameworks

CAPTA vs. CPS

CAPTA (Federal)	CPS (State)
"Plan of Safe Care" — supportive	Investigation — punitive
Notification for resources (WIC, home health)	Report for abuse/neglect
Being on prescribed MOUD is NOT abuse	State-specific criteria

      42 CFR Part 2 Update (Feb 2026): Single consent for Treatment, Payment, Operations (TPO)—aligns closer to HIPAA for care coordination between addiction psychiatry, OB, and pediatrics.
    

13 / 13

Takeaways

Clinical Pearls

MOUD is Standard: No detox in pregnancy
Dose for Physiology: Split doses in 3rd trimester
Prioritize Function: ESC for neonates, not Finnegan
The Cliff: Monitor 6-12 months postpartum
Legal Precision: POSC (support) vs CPS (punitive)
Topiramate Trap: Induces OCP metabolism + teratogen

"Stabilize the mother to save the baby."